A trial in Austria found that use of the company's device for GERD negated the need to take medication.
Medigus Ltd. (TASE:MDGS) will soon begin a clinical trial at the University of Rochester Medical Center in New York for the company's SRS endoscopic stapler for the treatment of gastroesophageal reflux disease (GERD). The trial is part of the company's effort to obtain marketing approval in the US.
Last week, Medigus announced the success of a trial with six patients in Austria. The patients were functioning normally and suffered no ill effects from the treatment. They no longer suffered from GERD and needed no medication for it.
Medigus has demonstrated the SRS endoscopic stapler on scores of patients worldwide, showing that it is equal in value to invasive surgery to staple the esophagus. The Austrian trial was the first to show that the device negated the need to take medication.
Published by Globes [online], Israel business news - www.globes-online.com - on September 18, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008